Retinitis Pigmentosa in 2026: Mapping the Shift from Supportive Care to Restorative Therapy, Thelansis Reports

Retinitis Pigmentosa (RP) has spent the better part of a decade waiting for its "next Luxturna moment." In 2026, that moment finally looks close, several late-stage programs are reporting durability data, filing timelines are firming up, and for the first time, sponsors are competing on differentiated Target Product Profiles rather than simply chasing "first-to-market." For anyone building a commercial strategy, licensing thesis, or portfolio prioritization model in inherited retinal disease, this is the year the RP landscape starts to look like a real market rather than a research field.
Here's what's changing, where the gaps still sit, and what it means for TPP design.

The Market Context: Still One Approved Therapy, But Not for Long
RP remains defined by a stark fact: Luxturna (voretigene neparvovec), approved in 2017, is still the only FDA-approved gene therapy touching this disease group and even that is narrowly indicated for RPE65-mediated disease, a small genetic slice of the broader RP population. Clinicians have been vocal about the gap this leaves; as one inherited retinal disease specialist put it earlier this year, it's hard to believe it's been nearly a decade since the last approval in the category.

That's set to change. Several programs are now within striking distance of filing:
• Mutation-agnostic modifier gene therapy - a Phase 3 program has completed enrollment with topline data expected in Q1 2027, positioning it as a potential broad-spectrum option across multiple RP genotypes rather than a single-mutation therapy.
• Optogenetic approaches - intravitreal, mutation-independent therapies designed for advanced RP with minimal remaining photoreceptor function; one program has already initiated a rolling BLA, and long-term (3-year) durability data presented at ARVO 2026 add real weight to the "restoration" narrative for a population once considered past the point of treatment.
• RNA-based therapies - targeting specific genotypes (e.g., PRPF31-linked RP11, USH2A exon 13 mutations) with encouraging early-phase signals, expanding the precision-medicine end of the pipeline.
• X-linked RP (RPGR) - a Phase 3 program changed hands via acquisition this year; while it missed its primary endpoint, consistent secondary-measure signals kept regulatory plans alive, with filings targeted across the US, EU, and Japan.

The result: a pipeline that is finally diversifying across modality (AAV gene replacement, gene-agnostic modifiers, optogenetics, RNA therapy) and across genotype, which matters enormously for how payers, physicians, and patients will eventually segment "which RP am I treating."

Our new report "Retinitis Pigmentosa (RP): Emerging Therapy, with Unmet Needs and TPP Insights - 2026" unpacks the competitive landscape, KOL-validated unmet needs, and target product profile (TPP) benchmarking teams need to plan a launch or licensing decision with confidence. Explore the full scope and download a sample: https://thelansis.com/reports/retinitis-pigmentosa-rp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/

Key Emerging Players Shaping the Category
The competitive set spans large gene-therapy specialists and smaller, genotype-focused biotechs, a structure that typically signals a market still being defined rather than consolidated:
• Sponsors advancing broad-spectrum, mutation-agnostic modifier therapies in late-stage trials
• Optogenetics-focused developers building on multi-year durability datasets, a rare asset this early in an RP program's life
• RNA-therapeutics specialists carving out genotype-specific niches (PRPF31, USH2A) via dedicated business units
• Programs that changed hands through licensing and acquisition this year, signaling that larger players are actively buying into RP rather than building from scratch, a meaningful commercial-interest signal for anyone assessing category attractiveness

This mix of modality and mutation-specific plays is precisely why a single "one-size-fits-all" commercial model won't work for RP; segmentation by genotype and disease stage will matter as much as segmentation by geography.

Secure your position in the emerging Retinitis Pigmentosa (RP) market by unlocking the critical pipeline benchmarks and TPP data driving the field forward. Request a Sample: https://thelansis.com/reports/retinitis-pigmentosa-rp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rp_tpp

Current Therapies and Standard of Care: Still Largely Supportive
Outside of the narrow RPE65-indicated gene therapy, RP management today remains largely supportive rather than restorative:
• Low-vision aids and rehabilitation services
• Nutritional/antioxidant approaches (e.g., ongoing Phase 3 evaluation of an FDA-approved NAC formulation for broader RP use)
• Genetic counseling and registry-based monitoring (natural history studies remain a major enrollment activity across academic centers)
• Adjunctive and complementary approaches used alongside specialist care, though without regulatory-grade efficacy data

This "watch and support" paradigm is precisely what the emerging pipeline is trying to displace and it's the baseline against which any new therapy's value story and TPP will be benchmarked.

Key Market Drivers and Trends
A few forces are converging to accelerate this category:
• Regulatory tailwinds - Fast Track, Orphan Drug, and PRIME-equivalent designations are now common across the leading programs, shortening review timelines and de-risking filing plans
• Durability data maturing - 3-year follow-up data presented at ARVO 2026 for optogenetic and neuroprotective approaches is shifting the conversation from "does it work" to "how long does it last," which is exactly the question payers will ask
• Genotype-agnostic designs gaining favor - sponsors increasingly favor modifier or optogenetic approaches precisely because they sidestep the addressable-population ceiling that single-mutation gene therapies face
• M&A and licensing activity - the RPGR-program acquisition this year is a signal that larger players view RP as a category worth buying into, not just monitoring

Durability data, designation timing, and genotype-agnostic design aren't just clinical footnotes; they directly shape payer negotiations, launch sequencing, and TPP defensibility.
Our report maps these drivers against a full competitive and forecast model, so your team isn't building strategy on trial headlines alone. Get the details in our full RP report: https://thelansis.com/reports/retinitis-pigmentosa-rp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rp_tpp

Key Unmet Needs and What KOLs Are Signaling
Despite the pipeline momentum, several gaps remain unresolved, and they're the gaps most likely to define winners and losers over the next five years:
• No approved options for advanced-stage or genotype-unknown patients. The bulk of the RP population still has nowhere to go, this is precisely the population optogenetic and modifier therapies are targeting, but none are approved yet.
• X-linked RP remains without an approved therapy. Despite being one of the more severe and well-characterized RP subtypes, RPGR-mediated disease has no approved intervention, a gap multiple sponsors are racing to close.
• Endpoint and outcome-measure standardization. Clinicians and regulators are still converging on what "meaningful visual improvement" looks like across such a heterogeneous disease group, a real complication for TPP-setting and label negotiations.
• Delivery burden. Subretinal surgical delivery, required by many gene-replacement approaches, remains a barrier to broad adoption relative to intravitreal alternatives, a factor increasingly built into next-generation TPPs.
• Diagnosis and genotyping access. Much of the current clinical-trial infrastructure is built around registries and natural history studies precisely because genotype confirmation is still not universal in practice, a real-world access gap that will shape addressable-population sizing.

These are the exact inputs that should be shaping how a TPP is written today, target population definition, delivery route, endpoint selection, and differentiation versus the emerging modifier and optogenetic entrants.

TPP Insights: What "Differentiated" Looks Like in 2026
Given the above, a defensible RP Target Product Profile in 2026 increasingly needs to address:
• Population breadth - genotype-agnostic positioning is emerging as a genuine competitive advantage over single-mutation therapies, given how fragmented RP genetics are
• Delivery route - intravitreal or non-surgical delivery is becoming a meaningful differentiator against subretinal administration
• Durability claims - multi-year follow-up data is quickly becoming table stakes for credibility with both clinicians and payers
• Disease-stage flexibility - profiles that can credibly address both early-stage (preservation) and late-stage (restoration) patients open a materially larger addressable market
• Regulatory pathway leverage - designations (Fast Track, Orphan Drug, PRIME) are being used earlier and more deliberately to shape both timeline and eventual pricing conversations

For sponsors and investors, the practical question is no longer "is there room in RP", clearly there is, but "which TPP dimensions will actually move the needle on adoption once two or three of these therapies are approved side by side."

Commercial Opportunity
With genotype-agnostic modifier therapies, optogenetics, and RNA-based approaches all converging toward approval within a similar window, RP is shaping up to be a genuinely competitive, not just a "first mover wins" category. That creates real commercial opportunity for:
• Sponsors positioning differentiated delivery or genotype-breadth ahead of an eventual multi-therapy market
• Investors and BD teams evaluating licensing or acquisition targets while genotype-specific niches (RPGR, PRPF31, USH2A) are still open
• Payers and market access teams beginning early value-framework planning ahead of multiple near-simultaneous launches

Ready to Go Deeper?
Access the full report here: Retinitis Pigmentosa (RP) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026: https://thelansis.com/reports/retinitis-pigmentosa-rp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rp_tpp

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

This release was published on openPR.